Faculty of Medicine and Health, School of Clinical Medicine, University of New South Wales, Sydney, New South Wales, Australia.
Department of Nephrology, Prince of Wales Hospital, Sydney, New South Wales, Australia.
Am J Physiol Renal Physiol. 2023 Dec 1;325(6):F888-F898. doi: 10.1152/ajprenal.00133.2023. Epub 2023 Sep 21.
Significant loss of kidney function is not easily identified by serum creatinine (sCr)-based measurements. In the presence of normal sCr, decreased kidney functional reserve (KFR) may identify a significant loss of function. We evaluated KFR in experimental subclinical chronic kidney disease (sCKD) before and after brief ischemia-reperfusion injury (IRI). Using fluorescein isothiocyanate-labeled sinistrin, glomerular filtration rate (GFR) was measured transcutaneously before and after adenine-induced sCKD, and 1 and 2 wk after brief IRI, and compared with urinary kidney damage biomarkers. sCKD reduced stimulated and unstimulated GFR by ∼20% while reducing KFR by 50%. IRI reduced unstimulated GFR for 14 days, but KFR remained relatively unchanged in sCKD and transiently increased in control kidneys at 7 days. sCr increased and creatinine clearance (CrCl) decreased only immediately after IRI; sCr and CrCl correlated poorly with measured GFR except on after IRI. Heterogeneity in sCr and CrCl resulted from variation in tubular creatinine secretion. The increase in damage biomarker concentrations persisted for up to 14 days after IRI, allowing retrospective detection of sCKD before AKI by urine clusterin/urine kidney injury molecule-1 with an area under the curve of 1.0. sCr and CrCl are unreliable unless sCr is acutely elevated. Measurement of KFR and urine damage biomarker excretion detected sCKD despite normal sCr and CrCl. After IRI, the urine clusterin-to-urine kidney injury molecule-1 ratio may identify prior sCKD. Early kidney function loss is poorly identified by serum creatinine (sCr)-based measurements. Direct kidney functional reserve (KFR) measurement before kidney injury and elevated urinary biomarkers clusterin and kidney injury molecule-1 detect subclinical chronic kidney disease (sCKD) after kidney injury despite normal range sCr and creatinine clearance. Reliance on sCr masks underlying sCKD. Acute kidney injury risk evaluation requires direct glomerular filtration rate measurement and KFR, whereas kidney damage biomarkers facilitate identification of prior subclinical injury.
血清肌酐(sCr)检测难以发现明显的肾功能丧失。在 sCr 正常的情况下,肾脏功能储备(KFR)降低可能表明存在明显的功能丧失。我们在实验性亚临床慢性肾脏病(sCKD)发生短暂缺血再灌注损伤(IRI)前后评估了 KFR。使用异硫氰酸荧光素标记的辛可宁,在腺嘌呤诱导 sCKD 前后以及短暂 IRI 后 1 和 2 周经皮测量肾小球滤过率(GFR),并与尿肾脏损伤生物标志物进行比较。sCKD 使刺激和非刺激 GFR 降低约 20%,同时使 KFR 降低 50%。IRI 使非刺激 GFR 降低 14 天,但 KFR 在 sCKD 中相对不变,在对照肾脏中短暂增加,在 7 天。sCr 升高,肌酐清除率(CrCl)在 IRI 后立即降低;sCr 和 CrCl 与测量的 GFR 相关性较差,除了在 IRI 后。sCr 和 CrCl 的异质性源于肾小管肌酐分泌的变化。损伤生物标志物浓度的增加持续至 IRI 后 14 天,允许通过尿液 clusterin/尿肾损伤分子-1 进行 AKI 前的 sCKD 回顾性检测,曲线下面积为 1.0。sCr 和 CrCl 不可靠,除非 sCr 急性升高。尽管 sCr 和 CrCl 正常,但 KFR 和尿液损伤生物标志物的测量可检测到 sCKD。IRI 后,尿 clusterin/尿肾损伤分子-1 比值可能识别之前的 sCKD。血清肌酐(sCr)检测不能很好地发现早期肾功能丧失。在发生肾脏损伤之前,直接测量肾脏功能储备(KFR)以及升高的尿生物标志物 clusterin 和肾损伤分子-1,可在发生肾脏损伤后检测到亚临床慢性肾脏病(sCKD),尽管 sCr 和肌酐清除率在正常范围内。对 sCr 的依赖掩盖了潜在的 sCKD。急性肾损伤风险评估需要直接测量肾小球滤过率和 KFR,而肾脏损伤生物标志物有助于识别先前的亚临床损伤。